CID-49830258
4物価
選択條件:
ブランド
- 富士フイルム和光純薬株式會(huì)社(wako)
- Sigma-Aldrich Japan
パッケージ
- 5mg
- 10mg
- 25mg
- 50mg
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01TOC5153
- 製品説明
- 英語(yǔ)製品説明ML 240
- 包裝単位50mg
- 価格¥309000
- 更新しました2024-03-01
- 購(gòu)入
- 生産者富士フイルム和光純薬株式會(huì)社(wako)
- 製品番號(hào)W01TOC5153
- 製品説明
- 英語(yǔ)製品説明ML 240
- 包裝単位10mg
- 価格¥73000
- 更新しました2024-03-01
- 購(gòu)入
- 生産者Sigma-Aldrich Japan
- 製品番號(hào)SML1071
- 製品説明 ≥98% (HPLC)
- 英語(yǔ)製品説明ML240 ≥98% (HPLC)
- 包裝単位5mg
- 価格¥22600
- 更新しました2024-03-01
- 購(gòu)入
- 生産者Sigma-Aldrich Japan
- 製品番號(hào)SML1071
- 製品説明 ≥98% (HPLC)
- 英語(yǔ)製品説明ML240 ≥98% (HPLC)
- 包裝単位25mg
- 価格¥72000
- 更新しました2024-03-01
- 購(gòu)入
生産者 | 製品番號(hào) | 製品説明 | 包裝単位 | 価格 | 更新時(shí)間 | 購(gòu)入 |
---|---|---|---|---|---|---|
富士フイルム和光純薬株式會(huì)社(wako) | W01TOC5153 | ML 240 |
50mg | ¥309000 | 2024-03-01 | 購(gòu)入 |
富士フイルム和光純薬株式會(huì)社(wako) | W01TOC5153 | ML 240 |
10mg | ¥73000 | 2024-03-01 | 購(gòu)入 |
Sigma-Aldrich Japan | SML1071 | ≥98% (HPLC) ML240 ≥98% (HPLC) |
5mg | ¥22600 | 2024-03-01 | 購(gòu)入 |
Sigma-Aldrich Japan | SML1071 | ≥98% (HPLC) ML240 ≥98% (HPLC) |
25mg | ¥72000 | 2024-03-01 | 購(gòu)入 |
プロパティ
沸點(diǎn) :696.6±65.0 °C(Predicted)
比重(密度) :1.35±0.1 g/cm3(Predicted)
貯蔵溫度 :2-8°C
溶解性 :DMSO: soluble5mg/mL, clear (warmed)
外見(jiàn) :powder
酸解離定數(shù)(Pka) :4.53±0.10(Predicted)
色 :white to yellow to light brown
比重(密度) :1.35±0.1 g/cm3(Predicted)
貯蔵溫度 :2-8°C
溶解性 :DMSO: soluble5mg/mL, clear (warmed)
外見(jiàn) :powder
酸解離定數(shù)(Pka) :4.53±0.10(Predicted)
色 :white to yellow to light brown
安全情報(bào)
絵表示(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
注意喚起語(yǔ): | ||||||||
危険有害性情報(bào): |
|
|||||||
注意書(shū)き: |
|
説明
The p97 AAA (ATPase associated with diverse cellular activities) uses energy from ATP hydrolysis to unfold proteins or disassemble protein complexes. p97 is a hexameric protein consisting of two AAA domains (D1 and D2) that form two stacked rings and an N-terminal domain that recruits cofactor/substrate specificity factors. It functions in many regulatory processes to maintain protein homeostasis and has become a therapeutic target for cancer and neurodegenerative diseases. ML-240 is an ATP-competitive inhibitor of the D2 domain of the p97 ATPase (IC50 = 0.11 μM; Ki = 0.22 μM). It disrupts the endoplasmic reticulum-associated degradation and autophagy pathways, preventing the degradation of p97-dependent proteasome substrates (IC50 = 0.9 μM) and causing accumulation of ubiquitin conjugates in nuclear membrane and cytosolic compartments at 5-10 μM. ML-240 has also been shown to block proliferation of HCT15 and SW403 colon cancer cell lines (GI50s = 0.76 and 0.5 μM, respectively) and to rapidly mobilize caspase-3 and -7, inducing apoptosis.関連製品価格
ML213 [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone 1-(3,4-ジフルオロフェニル)-3-(1-フェニル-3-メチル-1H-ピラゾール-5-イル)尿素 ML277 ML 18 ML-228 ML221 ML216 ML161 1-[(5-クロロ-1-ナフタレニル)スルホニル]ヘキサヒドロ-1H-1,4-ジアゼピン·塩酸塩 N-[4-(1H-1,2,3-トリアゾール-1-イル)ベンジル]-2-(2-イソプロピルフェニル)-5-メチル-4-ピリミジンアミン 4-[3-フェニル-5-(4-メトキシフェニル)-4,5-ジヒドロ-1H-ピラゾール-1-イル]ベンゼンスルホンアミド ML-7塩酸塩 4-Methyl-2-(1-piperidinyl)-quinoline M348 1-(4-(4-(benzo[d][1,3]dioxole-5-carbonyl)piperazin-1-yl)phenyl)ethan-1-one ML234 ML193 ML281 5-[6-(4-Methoxyphenyl)pyrazolo[1,5-a]関連商品価格
- ML213
¥16000-1068100 - [4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone
¥25600-95700 - 1-(3,4-ジフルオロフェニル)-3-(1-フェニル-3-メチル-1H-ピラゾール-5-イル)尿素
¥17000-235000
供給者とメーカー
ATK CHEMICAL COMPANY LIMITED
TargetMol Chemicals Inc.
HANGZHOU CLAP TECHNOLOGY CO.,LTD
InvivoChem
LEAP CHEM CO., LTD.
TargetMol Chemicals Inc.
ShenZhen Trendseen Biological Technology Co.,Ltd.
Shenyang Zhongshen Zekang Biomedical Technology Research Co., Ltd
Aladdin Scientific
Wuhan Jingkang en Biomedical Technology Co., Ltd